Insider Selling: Opiant Pharmaceuticals Inc (OPNT) Insider Sells $32,796.21 in Stock

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) insider Phil Skolnick sold 1,821 shares of the firm’s stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $18.01, for a total value of $32,796.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Phil Skolnick also recently made the following trade(s):

  • On Thursday, October 4th, Phil Skolnick sold 4,778 shares of Opiant Pharmaceuticals stock. The stock was sold at an average price of $18.32, for a total value of $87,532.96.

NASDAQ OPNT opened at $17.36 on Thursday. Opiant Pharmaceuticals Inc has a 52 week low of $12.75 and a 52 week high of $36.77. The stock has a market capitalization of $49.01 million, a PE ratio of 5.90 and a beta of 0.34.

Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its quarterly earnings data on Wednesday, November 7th. The technology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.21). Opiant Pharmaceuticals had a negative return on equity of 471.43% and a negative net margin of 449.52%. The company had revenue of $4.37 million during the quarter, compared to the consensus estimate of $4.70 million. On average, research analysts expect that Opiant Pharmaceuticals Inc will post -4.7 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Opiant Pharmaceuticals stock. Brasada Capital Management LP bought a new position in shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 15,000 shares of the technology company’s stock, valued at approximately $268,000. Brasada Capital Management LP owned approximately 0.50% of Opiant Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 4.51% of the company’s stock.

Several research firms have recently commented on OPNT. ValuEngine downgraded Opiant Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 28th. Cantor Fitzgerald set a $42.00 price objective on Opiant Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, September 28th.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Opiant Pharmaceuticals Inc (OPNT) Insider Sells $32,796.21 in Stock” was first reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Further Reading: How can investors find ex-dividend dates?

Insider Buying and Selling by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply